Table 1.
Baseline demographic characteristics (modified total vaccinated cohort and according-to-protocol cohorts for humoral and cell-mediated immunogenicity)
| Modified total vaccinated cohort, N = 1721 |
According-to-protocol cohort |
|||||
|---|---|---|---|---|---|---|
| Humoral immunity sub-cohort, N = 158 |
Cell-mediated immunity sub-cohort, N = 114 |
|||||
| Characteristic | RZV (N = 870) |
Placebo (N = 851) |
RZV (N = 82) |
Placebo (N = 76) |
RZV (N = 59) |
Placebo (N = 55) |
| Age (years) | ||||||
| Mean ± SD | 54.9 ± 11.5 | 55.1 ± 11.3 | 54.2 ± 11.8 | 56.5 ± 9.9 | 54.2 ± 10.5 | 55.6 ± 9.9 |
| Age group-no. (%) | ||||||
| 18–49 years | 213 (24.5) | 212 (24.9) | 26 (31.7) | 17 (22.4) | 20 (33.9) | 14 (25.4) |
| ≥50 years | 657 (75.5) | 639 (75.1) | 56 (68.3) | 59 (77.6) | 39 (66.1) | 41 (74.6) |
| Gender-no. (%) | ||||||
| Female | 323 (37.1) | 317 (37.3) | 29 (35.4) | 29 (38.2) | 18 (30.5) | 23 (41.8) |
| Male | 547 (62.9) | 534 (62.7) | 53 (64.6) | 47 (61.8) | 41 (69.5) | 32 (58.2) |
| Race-no. (%) | ||||||
| White | 686 (78.9) | 666 (78.3) | 60 (73.2) | 58 (76.3) | 48 (81.4) | 47 (85.5) |
| Black | 15 (1.7) | 23 (2.7) | 3 (3.7) | 1 (1.3) | 3 (5.1) | 1 (1.8) |
| Asian | 138 (15.9) | 139 (16.3) | 17 (20.7) | 16 (21.1) | 6 (10.2) | 6 (10.9) |
| Other | 31 (3.6) | 23 (2.7) | 2 (2.4) | 1 (1.3) | 2 (3.4) | 1 (1.8) |
| Underlying disease-no. (%) | ||||||
| Multiple myeloma | 472 (54.3) | 465 (54.6) | 44 (53.7) | 42 (55.3) | 33 (55.9) | 32 (58.2) |
| Other diseases | 398 (45.7) | 386 (45.4) | 38 (46.3) | 34 (44.7) | 26 (44.1) | 23 (41.8) |
| Non-Hodgkin B-cell lymphoma | 237 (27.2) | 244 (28.7) | . | . | 16 (27.1) | 12 (21.8) |
| Non-Hodgkin T-cell lymphoma | 43 (4.9) | 40 (4.7) | . | . | 3 (5.1) | 3 (5.5) |
| Hodgkin lymphoma | 74 (8.5) | 60 (7.1) | . | . | 1 (1.7) | 3 (5.5) |
| Acute myeloid leukemia | 20 (2.3) | 16 (1.9) | . | . | 2 (3.4) | 2 (3.6) |
| Solid malignancies and others | 24 (2.8) | 26 (3.1) | . | . | 4 (6.8) | 3 (5.5) |
| Other hematologic malignancies | 10 | 9 | . | . | 1 | 2 |
| Amyloidosis | 7 | 7 | . | . | 1 | 0 |
| Solid malignancies | 6 | 6 | . | . | 2 | 0 |
| Systemic sclerosis | 1 | 3 | . | . | 0 | 1 |
| Multiple sclerosis | 0 | 1 | . | . | 0 | 0 |
N = number of participants included in each group; no. (%) = number (percentage) of participants in each category; SD = standard deviation; RZV = adjuvanted recombinant zoster vaccine.